{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 24,
  "pageCount": 31,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide outlines a licensing deal structure and clinical progress.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/24",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "BeiGene holds an exclusive global license to BA3071; BioAtla has received $25 million in upfront payments; BioAtla eligible to receive up to $225.5 million for milestones; BioAtla eligible to receive tiered royalties of up to low 20's",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "147193da-2600-4a1d-a747-f6516d90d95e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "Expected Phase 1 dose escalation trial in 2021; Doses of 7mg Q3W to 700mg Q3W; Tislelizumab is an anti-PD-1 antibody; BeiGene leads Development, Manufacturing and Commercialization",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "201dacc5-930d-4b31-934a-100a1813a1f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: ¹Equivalent to 10mg/kg of ipilimumab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9b3093f-9bb2-4612-a156-610189cd0067",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BA3071: Global Strategic Collaboration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59d5d2e7-f7a1-4ea1-9224-e21ea4cfd286",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2da41733-ee60-4ac5-956c-21766b365f10",
      "evidence": "The slide presents a collaboration with a clear call to action and attention-grabbing information.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "426c9e34-7091-4e35-85fe-e86bd0b5fb99",
      "evidence": "The document implies the cost of inaction by presenting the potential benefits of BioAtla's technology.",
      "position": 0,
      "objective": "What is the cost of not adopting BioAtla's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}